Mitralign Garners $39,800,000 Series E Funding

  • Feed Type
  • Date
  • Company Name
  • Mailing Address
    3 Highwood Drive Tewksbury, MA 01876 USA
  • Company Description
    We are currently developing an innovative, catheter- based mitral valve repair system that not only provides an alternative to open heart surgery but emulates the traditional surgical repair technique. The condition treated,mitral valve regurgitation (MR), is common in patients with Congestive Heart Failure.
  • Website
  • Transaction Type
    Venture Equity
  • Transaction Amount
  • Transaction Round
    Series E
  • Proceeds Purposes
    The Company plans to continue growing its platform by pursuing US and CE regulatory approval for the commercialization of their Trialign system in parallel with preparations for commercial launch in Europe of their Mitralign Percutaneous Annuloplasty System (MPAS).
  • M&A Terms
  • Venture Investor

Trending on Xconomy